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Resurrection of non-processed pseudogenes may increase the ef-
ficacy of therapeutic gene editing, upon simultaneous targeting
of a mutated gene and its highly homologous pseudogenes. To
investigate the potency of this approach for clinical gene therapy
of human diseases, we corrected a pseudogene-associated disor-
der, the immunodeficiency p47phox-deficient chronic granulo-
matous disease (p47phox CGD), using clustered regularly inter-
spaced short palindromic repeats-associated nuclease Cas9
(CRISPR-Cas9) to target mutated neutrophil cytosolic factor 1
(NCF1). Being separated by less than two million base pairs,
NCF1 and two pseudogenes are closely co-localized on chromo-
some 7. In healthy people, a two-nucleotide GT deletion (DGT)
is present in the NCF1B and NCF1C pseudogenes only. In the
majority of patients with p47phox CGD, the NCF1 gene is inacti-
vated due to a DGT transfer from one of the two non-processed
pseudogenes. Here we demonstrate that concurrent targeting
and correction of mutated NCF1 and its pseudogenes results
in therapeutic CGDphenotype correction, but also causes poten-
tially harmful chromosomal deletions between the targeted loci
in a p47phox-deficient CGD cell line model. Therefore, develop-
ment of genome-editing-based treatment of pseudogene-related
disordersmandates thorough safety examination, as well as tech-
nological advances, limiting concurrent induction of multiple
double-strand breaks on a single chromosome.
INTRODUCTION
Chronic granulomatous disease (CGD) is characterized by defec-
tive respiratory burst,1 impaired microbicidal activity of phago-
cytes,2,3 and resulting life-threatening bacterial and fungal infec-
tions. This condition is caused by mutations of genes encoding
gp91phox, p22phox, p67phox, p47phox, or p40phox subunits of the
phagocytic nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase complex. In nearly all patients with p47phox
CGD, the disease is caused by a two-nucleotide GT deletion
(DGT) within exon 2 of the neutrophil cytosolic factor 1 (NCF1)
gene.4,5 This DGT mutation causes a frameshift and an early trans-
lation termination. NCF1 is accompanied on chromosome 7 by two
almost identical non-processed pseudogenes, NCF1B and NCF1C,
which carry the DGT mutation also in healthy individuals.6,7
Although retroviral-based hematopoietic stem cell (HSC) gene
therapy has been clinically successful in patients with the X-linked
gp91phox-deficient form of CGD,8,9 autosomal recessive p47phox
CGD has not been successfully addressed in gene therapy trials
yet. Because more than 97% of patients with p47phox CGD share
the same DGT mutation, genome-editing-based gene therapy
may constitute an attractive alternative to lentiviral gene therapies
for this subgroup of patients.
In general, genetic disorders such as p47phox CGD caused by muta-
tion transfer from non-processed pseudogenes are particularly
promising targets for genome editing, because parallel gene and
pseudogene resurrection via the presence of highly homologous
target sites may potentially increase the overall efficiency of the
treatment. If the gene and pseudogene are located on the same chro-
mosome, however, editing inducing double-strand breaks (DSBs)
may cause chromosomal deletions as a side effect. At least 11 re-
ported genetic disorders are associated with pseudogene-related
gene conversion (Table S1),10,11 making them potentially attractive,
but challenging targets for genome editing. In the case of p47phox
CGD, the DGT mutation may be directly targeted and corrected,
leading to conversion of the inactive NCF1 loci into p47phox-express-
ing genes. However, for other pseudogene-related disorders, various
strategies may be considered, including exon replacement or mini-
gene insertion.12,13
As a model representing pseudogene-related genetic disorders,
here we study the efficacy and safety of genome editing of p47phox
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CGD by clustered regularly interspaced short palindromic repeats-as-
sociated nuclease Cas9 (CRISPR-Cas9). Diverse genome-editing sys-
tems (CRISPR-Cas9, zinc-finger nucleases [ZFNs], transcription acti-
vator-like effector nucleases [TALENs]) have been used preclinically
for correction of CGD in cell line models14–16 and in human HSCs by
cDNA delivery to a safe genomic harbor,17,18 by exon replacement,12
or by direct mutation targeting.19,20 Interestingly, ZFN-mediated
correction of NCF1 pseudogenes in induced pluripotent stem cells
(iPSCs) resulted in the expression of functional p47phox upon phago-
cytic differentiation.19Whereas these studies focused primarily on the
efficacy of CGD correction, we set out to evaluate the safety of DGT
p47phox CGD correction in a cell line model of p47phox CGD.21
RESULTS
Reconstitution of p47phox Expression and NADPH Oxidase
Function upon CRISPR-Cas9-Mediated Correction of NCF1
Gene and Pseudogene Loci
First, the PLB-985 wild type (WT) and the corresponding isogenic
p47phox CGD model cell line, PLB-985 NCF1 DGT,21 were nucleo-
fected with a CRISPR-Cas9 and GFP co-expressing plasmid, along
with a corrective single-stranded oligodeoxynucleotide (ssODN) tem-
plate (Figure 1A). Single-guide RNA (sgRNA) sequences were de-
signed to guide Cas9 to the DGT mutation site in mutated NCF1,
which is also present in NCF1B and NCF1C pseudogenes (Figure 1B).
The on-target correction efficiency in Cas9-expressing cells was deter-
mined by PCR-based restriction fragment length polymorphism
(RFLP) method (PCR-RFLP) that detects restoration of the BsrGI re-
striction site upon correction, quantified as GTGT content in
genomic DNA derived from edited cells (Figures 1B and 1C).
This analysis demonstrated that the DGT mutation within the NCF1
gene and its pseudogenes can be corrected, and that two out of three
tested sgRNAs (sgRNA #1 and #2; Figures 1B and 1C) successfully re-
constituted the BsrG1 restriction site (Figure 1B), restoring the
normalNCF1 gene sequence. The efficiencies ofNCF1 gene and pseu-
dogene loci correction corresponded to the GTGT content values
observed for clinically healthy DGT p47phox CGD carriers.22 Esti-
mated GTGT content values for CRISPR-Cas9-treated PLB-985
NCF1 DGT bulk cultures were 0.22 ± 0.02 and 0.17 ± 0.02 for sgRNA
#1 and #2, respectively, suggesting that on average one NCF1 gene or
one pseudogene locus was corrected in Cas9-expressing cells. Inter-
estingly, CRISPR-Cas9 treatment of PLB-985 WT cells led to an in-
crease of the GTGT content, from 0.39 ± 0.04 (untreated) to 0.70 ±
0.03, indicating the correction of NCF1B or NCF1C pseudogenes.
High efficacy of CRISPR-Cas9 editing was observed for all tested
sgRNAs, as additionally assayed by TIDER (tracking of insertions, de-
letions, and recombination events by decomposition) method (Fig-
ure 1D).23 Due to the highly homologous NCF1 gene and pseudogene
loci in humans, as well as a naturally present DGT in NCF1 pseudo-
genes, TIDER analysis of PLB-985 WT cells, performed on PCR co-
amplified NCF1 gene and pseudogene loci, detects the correct NCF1
gene as “cleaved and corrected.” Therefore, the estimated reference
cleavage and correction frequencies for the CRISPR-Cas9-untreated
wild-type cells were 46.4% ± 1.3% and 41.8% ± 0.7%, respectively.
The cleavage efficiency determined for CRISPR-Cas9-treated PLB-
985 WT cells was 93.3% ± 1.7%, and the correction efficiency was
63.1% ± 5.6%.
The true cleavage and correction efficacies in PLB-985 WT cells, cor-
responding to the difference between values detected in CRISPR-
Cas9-treated and untreated cells, confirmed the results observed
with PCR-RFLP. In CRISPR-Cas9-treated PLB-985 NCF1 DGT
bulk cultures, all tested sgRNAs exhibited high levels of cleavage effi-
ciency: 89.8% ± 0.6%, 56.8% ± 4.4%, and 81.9% ± 6.5% for sgRNAs
#1, #2, and #3, respectively. Correction of the DGT mutation was
observed only with sgRNAs #1 and #2, reaching 29.3% ± 0.9% for
sgRNA #1 and 18.9% ± 2.0% for sgRNA #2 (Figure 1D), confirming
the results of the PCR-RFLP analysis (Figure 1C).
Analysis of p47phox protein expression in CRISPR-Cas9-treated cells
(Figure 1E) showed that correction of the NCF1 pseudogenes in
PLB-985 WT cells led to increased p47phox expression. Correction
of PLB-985 NCF1 DGT (achieved with sgRNA #1 and #2) restored
p47phox protein expression. In addition, the NADPH oxidase function
was reconstituted in CRISPR-Cas9-treated PLB-985NCF1 DGT cells,
as measured by nitroblue tetrazolium (NBT) test (Figure 1F).
Remarkably, CRISPR-Cas9 treatment of PLB-985 NCF1 DGT cells
without corrective template also reconstituted NADPH oxidase func-
tion, although in fewer cells. This was not due to alternative splicing,
but likely occurred because of the reading frame-restoring indel mu-
tations in NCF1 (Figure S1).
Simultaneous Editing of ThreeNCF1Gene and Pseudogene Loci
Present on Chromosome 7 Leads to Complex Genomic
Aberrations
To characterize potential adverse effects of concurrent CRISPR-Cas9
targeting of NCF1 gene and pseudogene loci, we generated single
clones of CRISPR-Cas9-treated (sgRNA #1) PLB-985 NCF1 DGT
cells (Figures S2–S6). The sgRNA #1 has been selected for subsequent
experiments because it showed the highest specificity in cleaving the
DGT carrying sequence among tested sgRNAs (Figure S2). The T7
Endonuclease I assay performed on the top predicted off-target sites
showed high specificity of sgRNA #1 toward the mutated NCF1 and
NCF1 pseudogenes (Figure S7A; Table S2). GUIDE sequencing
(GUIDE-seq) analysis24 revealed three off-target sequences, of which
one is represented within five distinct genomic locations in the prox-
imity of members of a large multigene family, olfactory receptors
(Figure S7B; Table S3).25 Analysis by single-molecule real-time
(SMRT) sequencing26 of the NCF1/NCF1B/NCF1C PCR co-amplifi-
cation products, surrounding the DGT mutation of CRIPSR-Cas9-
treated PLB-985 NCF1 DGT individual clones, revealed high fre-
quency of indel mutations at the NCF1 on-target site, exceeding
90% of reads from non-corrected NCF1 gene or pseudogene loci
(Table S4). Sixty percent of Cas9-expressing clones exhibited cor-
rected reads (Figure S3A). Furthermore, 5 out of 45 tested clones car-
ried a 0.5-kb deletion at the CRISPR-Cas9 cut site that deleted NCF1
exon 2 (Figure 2A) and affected the results observed by PCR-RFLP
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(Figure S3B). Complementarity between the genomic sequences adja-
cent to the deleted region (Figure 2A) likely contributed to the induc-
tion of this deletion upon DSBs repair.
In addition to the observed indel formation, simultaneous CRISPR-
Cas9 cleavage of two or three DGT-carrying NCF1 loci that are
located on the same chromosomemay also lead to large chromosomal
rearrangements, which could span the regions between NCF1B and
NCF1 (1.5 Mb), NCF1 and NCF1C (0.4 Mb), or NCF1B and NCF1C
(1.9 Mb) (Figure 2B). We therefore quantified copy number variation
(CNV) using quantitative PCR (qPCR) of non-repetitive genes,
located between NCF1 loci (EIF4H between NCF1B and NCF1;
WBSCR16 between NCF1 and NCF1C) and genes located outside of
the NCF1 gene and pseudogene loci (CALN1 upstream of NCF1B;
HIP1 downstream of NCF1C) (Figures 2B and 2C; Table S5). We
identified 8 out of 49 clones (Figure 2C) that exhibited unaltered
copy number of CALN1 and HIP1 genes located outside the NCF1
gene and pseudogene loci, but decreased copy number of EIF4H
Figure 1. CRISPR-Cas9 Correction of the DGT Mutation in PLB-985 WT and PLB-985 NCF1 DGT Cells
(A) Scheme depicting the correction strategy ofNCF1 gene and pseudogene loci by CRISPR-Cas. (B) NCF1 locus: sequence of tested sgRNAs, cleavage sites for Cas9 (red
arrowheads), position of theDGTmutation (filled red rectangle), protospacer adjacent motifs (PAMs) (blue rectangles), correctedNCF1 sequence (green rectangle), digestion
sites for BsrG1 (orange arrowheads), and the BsrG1 restriction site (orange rectangle). (C) Polyacrylamide gel of PCR-RFLP analysis of bulk CRISPR-Cas9-treated PLB-985
WT and PLB-985 NCF1 DGT cell lines. Band intensities were analyzed by the displayed formula. The 161-bp band within the dashed rectangle resulted from digestion of
corrected NCF1 (n = 4; bars: means with standard deviations; statistical analysis with unpaired t test with Welch’s correction, **p < 0.01, ***p < 0.001). (D) TIDER analysis of
cleavage and correction efficiencies for bulk CRISPR-Cas9-treated and untreated PLB-985 WT and PLB-985 NCF1 DGT cell lines (n = 4; bars: means with standard
deviations; statistical analysis with unpaired t test with Welch’s correction, *p < 0.05, **p < 0.01, ***p < 0.001). (E) Western blot of control p67phox (another cytosolic NADPH
oxidase subunit, which is complexed with p47phox and p40phox, p47phox, andGAPDH for differentiated bulk CRISPR-Cas9-treated PLB-985WT and PLB-985NCF1DGT cell
lines. (F) Light microscopy images of NBT test performed on differentiated bulk CRISPR-Cas9-treated PLB-985 WT and PLB-985 NCF1 DGT cell lines. ns, not significant.
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and WBSCR16, located between NCF1 gene and pseudogenes, sug-
gesting the presence of heterozygous deletions between NCF1B and
NCF1C. Interestingly, one clone exhibited decreased CNV only for
WBSCR16, suggesting a heterozygous deletion between NCF1 and
NCF1C. No clones were identified with a homozygous deletion of
genes between NCF1 gene and pseudogene loci, which could result
from reduced viability due to homozygous deletion of genes affecting
cellular fitness.
Subsequently, all clones were tested for the presence of deletions be-
tween NCF1B and NCF1 by fluorescence in situ hybridization (FISH)
(Figure 2B), and a genome-wide analysis of chromosomal aberrations
Figure 2. Detection of Chromosomal Aberrations in CRISPR-Cas9-Treated PLB-985 NCF1 DGT Cells
(A) PCR product of NCF1 gene and pseudogene loci, with indicated primers. DGT, deletion-end adjacent partially complementary sequences, and detected deletion (red)
between them are indicated. (B) Scheme of chromosome 7 q11.23 fragment: locations of FISH probes, CEP7, binding the centromere of chromosome 7, and RP11-100C23,
binding the region between NCF1B and NCF1, as well as binding sites of four primer pairs used for CNV analysis are shown. A, B and C indicate the amplified chromosomal
segments; c (centromeric), m (medial), and t (telomeric) sites. Location ofNCF1,NCF1B, andNCF1C in blocks Bm, Bc, and Bt, respectively, is indicated by gray arrowheads.
(C) Relative copy number of regions surrounding NCF1 gene and pseudogene loci in CRISPR-Cas9-treated PLB-985 NCF1 DGT cells determined by qPCR. Clones with
deletion betweenNCF1B andNCF1C (red squares) and clones with deletion betweenNCF1 andNCF1C (red circles) are shown. (D) Number of CRISPR-Cas9-treated clones
that exhibited no chromosomal aberrations within NCF1 loci (blue), number of clones with a 0.5-kb deletion at the CRISPR-Cas9 cleavage site (gray), and heterozygous
deletions between NCF1 and NCF1C (yellow) and between NCF1B and NCF1C (red) confirmed by FISH and aCGH. (E) Immunofluorescence microscopy images of FISH
analysis for a control clone with centromeric CEP7 Spectrum Aqua binding and with binding sites for RP11-100C23 Fluorescein probe on two chromosomes, as well as a
clone with a heterozygous deletion of the region betweenNCF1B andNCF1 (binding of RP11-100C23 on one chromosome). (F) aCGH of chromosome 7 q11.22-23 region of
untreated PLB-985 NCF1 DGT cells and one clone of CRISPR-Cas9-treated PLB-985 NCF1 DGT without (no deletion) and two clones with a heterozygous deletion are
shown.
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was performed on selected clones using microarray-based compara-
tive genomic hybridization (aCGH) (Figures 2C and 2F; Figure S6;
Tables S6 and S7). FISH and aCGH analyses confirmed deletions be-
tween NCF1B and NCF1C detected by qPCR, and aCGH identified a
second clone with a deletion between NCF1 and NCF1C (Figures 2C–
2F). Duplications or chromosomal translocations within these
regions were not observed, which suggests that deletions of chromo-
somal fragments are the predominant chromosomal aberration type
after gene editing (see clones 21 and 27 in Figure S6 and Table S7).
DISCUSSION
Although holding great promises to potentially cure monogenetic dis-
eases at their origin, application of gene-editing technologies has also
been linked to unpredictable and complex editing outcomes at the
targeted site,27 which is a major hindrance to application of DSB-
based gene editing in clinical settings. Our results suggest that
CRISPR-Cas9-based gene therapy may indeed efficiently correct
mutated NCF1 and its pseudogenes, and thus rescue the impaired
NADPH oxidase activity in DGT p47phox CGD patients. However,
simultaneous induction of two or three DSBs on a single chromosome
can be associated with induction of large chromosomal aberrations
that primarily affect the sequences between the targeted loci, as we
and others have shown.28–32
The genotype of cells with CRISPR-Cas9-induced heterozygous dele-
tions within NCF1 gene and pseudogene loci resembles the genotype
present in patients with Williams syndrome.33 Haploinsufficiency of
genes residing in the deleted region is primarily linked to cardiovas-
cular and neurological manifestations of Williams syndrome.
Hemizygosity of the elastin (ELN) gene has been linked to the connec-
tive-tissue abnormalities and hypertension, whereas hemizygosity of
other genes has been associated with impaired visuospatial and motor
abilities, as well as with mild-to-moderate intellectual disability.
Although Williams syndrome is generally not considered as a can-
cer-predisposing condition, reports linking the reduced copy number
of the BCL7B gene that is located between NCF1B and NCF1 to blood
malignancies exist.34,35 A homozygous intra-chromosomal deletion
of the region between NCF1 gene and pseudogene loci has not been
observed in clones of CRISPR-Cas9-treated PLB-985 NCF1 DGT
cells. Although after gene editing of the NCF1 loci of a DGT
p47phox CGD patient, the deleted chromosomal fragments would be
restricted to cells of the hematopoietic compartment, their long-
term impact and potential adverse functional implications need to
be evaluated carefully.
As we demonstrate for pseudogene-associated p47phox CGD, the risk
for inducing chromosomal deletions is likely to apply to other
diseases caused by mutations associated with highly homologous
pseudogenes located on the same chromosome, such as autosomal
dominant polycystic kidney disease,36 type 2 Gaucher disease,37 or
neural tube defects.38 For later clinical application, future studies
will thus require a substantial improvement of gene-editing enzyme
delivery protocols, or application of different editing strategies, and
development of rigorous post-editing diagnostic protocols. Measures
to minimize adverse effects could include tightly controlled transient
exposure of the genome to the gene-editing enzyme, application of
other gene-editing strategies not generating DSBs, or modulation of
repair pathway choice after DSB generation. Base editors39 inducing
NCF1 exon 2 skipping by targeting the splice acceptor site adjacent
to theDGTmutation may not lead to reconstitution of the phagocytic
NADPH oxidase activity (Figures S1B–S1F); however, introduction of
missing nucleotides at the DGT mutation without induction of DSBs
by prime editors40 may constitute an appealing treatment alternative.
In conclusion, safety evaluation is of paramount importance for pre-
clinical development of gene-editing-based approaches, especially for
pseudogene-related diseases, where targeted genes and homologous
pseudogenes are co-localized on the same chromosome. The extent
of chromosomal aberrations, as well as their potential effects on the
patient’s health, should be carefully addressed in preclinical studies
on genome-editing gene therapy approaches, especially for pseudo-
gene-related diseases (Table S1). As to the current state of the art,
the application of gene-editing technology for treatment of pseudo-
gene-related genetic disorders should therefore be limited to those
cases in which the therapy provides immediate amelioration of life-
threatening symptoms or the therapeutic benefit for the patient bal-
ances out the risk for potential adverse effects.
MATERIALS AND METHODS
Plasmid Construction
The sgRNA sequences were designed using the Optimized CRISPR
Design (F. Zhang laboratory, MIT, 2015; http://zlab.bio/guide-
design-resources). Single-stranded DNA oligonucleotides were ob-
tained from Microsynth (Balgach, Switzerland), cloned into
pSpCas9(BB)-2A-GFP (PX458) (F. Zhang, Addgene plasmid
#48138),41 and the plasmid sequence was confirmed by Sanger
sequencing (Microsynth).
Cell Culture Conditions
PLB-985 WT and PLB-985 NCF1 DGT cell lines21 were cultured in
RPMI 1640 medium (PAN-Biotech, Aidenbach, Germany), supple-
mented with 10% (v/v) fetal calf serum (FCS) (PAN-Biotech),
100 U/mL penicillin, and 100 mg/mL streptomycin (Thermo Fisher
Scientific, Reinach, Switzerland). For granulocytic differentiation,
cells were cultured for 7 days in RPMI 1640 medium supplemented
with 5% (v/v) FCS, 100 U/mL penicillin, 100 mg/mL streptomycin,
and 0.5% (v/v) N,N-dimethylformamide (DMF) (Sigma Aldrich,
Buchs, Switzerland). Throughout all experiments, cells were grown
at 37C in a humidified atmosphere containing 5% (v/v) CO2.
CRISPR-Cas9 Treatment of the PLB-985 NCF1 DGT Cell Line
PX458 plasmids (15–40 mg) expressing sgRNA, Cas9, and GFP pro-
teins were delivered into 2  106 PLB-985 WT or PLB-985 NCF1
DGT cells by nucleofection, using the Amaxa Cell Nucleofector Kit
V and Amaxa Nucleofector II, program C-023 (Lonza, Basel,
Switzerland), along with a 100-nt ssODN (Microsynth) at a final con-
centration of 3 mM (Figure 1A). The sequence of the ssODN was:
50-GCC TCT TTG GAG GCT GAA TGG GGT CCC CCG ACT
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CTG GCT TTC CCC CAG GTG TAC ATG TTC CTG GTG AAA
TGG CAGGAC CTG TCGGAGAAGGTGGTC TAC C-30. The lo-
cations of the binding sites for sgRNA are presented in Figure 1B. Nu-
cleofected cells were supplemented with 500 mL growth medium and
incubated at room temperature for 10 min, and cells were transferred
to 10mL growthmedium thereafter. 1 mMSCR7 (BioVision,Milpitas,
CA, USA) was added 3–4 h after nucleofection, and cells were
cultured for 48 h. GFP-positive cells were sorted into a bulk culture
(FACSAria III FCF; Becton Dickinson, Allschwil, Switzerland) in pre-
conditioned, sterile filtered growth medium supplemented with 1 mM
SCR7. Sorted cells were expanded for 1 month, and individual clones
were generated by limiting dilution.
Assessment of Correction Efficacy by PCR-RFLP and TIDER
Genomic DNA of CRISPR-Cas9-treated cells was isolated using
DNeasy Blood & Tissue Kit (QIAGEN, Hombrechtikon,
Switzerland). Correction efficiency was assessed by PCR-RFLP
method, as described previously.22 In brief, PCR co-amplification
products of NCF1, NCF1B, and NCF1C were digested with BsrG1
and Pst1 restriction enzymes, and developed by electrophoresis in a
7.5% polyacrylamide gel. GTGT content was calculated based on
size-normalized band intensities. The band intensity 169 bp was
divided by the sum of band intensities 181 and 201 bp (Figure 1C).
TIDER analysis23 was performed using an online tool (https://tider.
deskgen.com/) to assess CRISPR-Cas9 editing efficiency. Approxi-
mately 590 bp PCR products of NCF1 and its pseudogenes were
amplified using the forward primer, 50-CCA AGGT CTC AAG
CAA TTC TCC-30, and the reverse primer, 50-CCA AAG GGT
GGAGCTGGAAC-30. TIDER analysis was performed on the Sanger
sequencing chromatograms using the default parameters of the tool.
SMRT Sequencing
Barcoded PCR co-amplification products derived from the CRISPR-
Cas9-treated PLB-985 NCF1 DGT clones (i.e., DGT carrying NCF1
and its pseudogenes) had a size of approximately 2.4 kb and were pro-
duced using combinations of the following barcoded forward (Fwd)
and reverse (Rev) primers: Fwd1, 50-TTA GGT CTA GGA TCC
AGT CAA GGA T-30; Fwd2, 50-AAA GGA TCC AGT CAA GGA
TCA ATG T-30; Fwd3, 50-TTT TCA GGT CTA GGA TCC AGT
CAA-30; Rev1, 50-TTA GGT TCT GGG AGA TCC TGT CT-30;
Rev2, 50-AAG TTC TGG GAG ATC CTG TCT GTT-30; Rev3,
50-CCA GCA GGT GCA TTT ATT TGG G-30. Gel-purified amplifi-
cation products were pooled and analyzed by the Functional Geno-
mics Center Zurich, University of Zurich, and ETH Zurich, Zurich,
Switzerland, as described before.21
Western Blot
Protein isolation from differentiated PLB-985 WT, PLB-985 NCF1
DGT, and CRISPR-Cas9-treated PLB-985 WT or PLB-985 NCF1
DGT cells was performed as described previously.42 In brief, cells
were homogenized in a modified radioimmunoprecipitation assay
(RIPA) lysis buffer and centrifuged for 10 min at 13,000 g. Protein
content in the supernatant was analyzed by Bradford assay (Sigma
Aldrich). 10 mg total protein was denatured by boiling in a modified
Laemmli loading buffer, separated by SDS-PAGE using 10% poly-
acrylamide gel, and wet-transferred onto Amersham Protran Pre-
mium NC nitrocellulose membrane (GE Healthcare Life Sciences,
UK). The membrane was blocked with 3% skim milk and immune
stained using the following primary antibodies: mouse anti-human
p47phox monoclonal antibody clone 1 (Becton Dickinson, Allschwil,
Switzerland), mouse anti-human p67phox monoclonal antibody
clone D-6, or mouse anti-human GAPDH monoclonal antibody
(0411) (both from Santa Cruz Biotechnology, Heidelberg, Ger-
many). The membrane was incubated overnight with primary anti-
bodies diluted 1:500 in an antibody buffer at 4C, followed by 1-h in-
cubation at room temperature with the mouse IgG kappa binding
protein conjugated to horseradish peroxidase (Santa Cruz Biotech-
nology) diluted 1:3,000. The signal was developed by incubation of
the membrane in SuperSignal West Pico PLUS Chemiluminescent
Substrate (Thermo Fisher Scientific), visualized with ImageQuant
LAS 4000 Biomolecular Imager (GE Healthcare Life Sciences, UK).
Densitometric analysis of protein bands was performed using
ImageJ.43
NBT Test
Differentiated PLB-985 WT, PLB-985 NCF1 DGT, and CRISPR-
Cas9-treated clones of PLB-985 NCF1 DGT cells were incubated in
100 mg/mL phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich)
and 200 ng/mL NBT for 30 min at 37C and 5% CO2 followed by cell
fixation in 1% (w/v) formaldehyde. Fixed cells were analyzed visually
for the presence of formazan precipitates using a Leica DM IL Fluo
light microscope equipped with a DFC420 digital camera and LEICA
application suite acquisition software (Leica Microsystems, Glatt-
brugg, Switzerland).
Chemiluminescence Assay
Chemiluminescence assay was performed on differentiated CRISPR-
Cas9-treated PLB-985 cells in 96-well plates. A total of 1  105 cells/
well were mixed with 200 mM luminol and 200 ng/mL PMA. Chem-
iluminescence signal was recorded with a Mithras LB 940 Multimode
Microplate Reader (Berthold Technologies, Zug, Switzerland).
CNV Assessment by qPCR
The CNV of genomic locations surrounding theNCF1 gene and pseu-
dogene loci in individual clones of CRISPR-Cas9-treated PLB-985
NCF1 DGT cells was assessed by qPCR. Primer sequences are listed
in Table S5, and primer annealing locations are displayed in Figure 2B.
qPCR was performed with the QuantStudio 7 Flex Real-Time PCR
System (Thermo Fisher Scientific) in 384-well plates, using
2.5 ng/mL genomic DNA in a total reaction volume of 10 mL,
500 nM forward and reverse primers, and SsoAdvanced Universal
SYBR Green Supermix (Bio-Rad Laboratories, Cressier, Switzerland).
PCR conditions included initial denaturation at 95C for 3 min, 40
cycles of 30-s denaturation at 95C, 30-s primer annealing at 65C,
and 15-s elongation at 72C. Obtained mean cycle threshold (Ct)
values of three measurements from individual plates were used for
calculation of mean Ct values of at least three independent
www.moleculartherapy.org
Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020 941
measurements. Relative copy number values of tested genomic re-
gions were calculated using the 2DDCt method.44
FISH
Chromosome preparations of individual CRISPR-Cas9-treated PLB-
985 NCF1 DGT clones were performed according to the manufac-
turers’ instructions. In brief, cells were incubated in hypotonic
0.075 M KCl solution for 30 min at 37C, followed by dropwise fixa-
tion, and subsequent three rounds of washing with fixative solution
(methanol:acetic acid; v/v 3:1 ratio). Fixed cells were dropped on a
microscopic slide and hybridized with FISH probes. The FISH probes
used for hybridization were a chromosome 7 centromere binding
probe Vysis CEP7, labeled with Spectrum Aqua (Abbott, Abbott Mo-
lecular, Baar, Switzerland), and a BAC library probe RP11-100C23,
conjugated to Green 5-Fluorescein dUTP (Empire Genomics, Buffalo,
NY, USA). The slides were denatured at 75C for 5 min, followed
by overnight hybridization at 37C and humid conditions using a
Leica ThermoBrite System (Biosystems Switzerland, Muttenz,
Switzerland). Then the slides were rinsed with a 0.4 saline sodium
citrate (SSC)/0.3% (v/v) IGEPAL buffer (Sigma Aldrich) for 120 s
at 72C ± 2C and 2 SSC/0.1% (v/v) IGEPAL (Sigma-Aldrich) for
60 s at room temperature. The slides were air-dried, and the nuclei
of hybridized cells were visualized with Vectashield Mounting Me-
dium containing DAPI (REACTOLAB, Servion, Switzerland). Micro-
scopic images were acquired using the Axio Imager.Z2 microscope
(Carl Zeiss, Feldbach, Switzerland) and analyzed using Isis software
(MetaSystems Hard & Software, Altlussheim, Germany). For each
tested clone, at least 200 interphase nuclei were analyzed.
aCGH
The PLB-985 NCF1 DGT cell line, as well as selected CRISPR-Cas9-
treated PLB-985 NCF1 DGT clones, were subjected to aCGH using
the CytoScan HD Array Kit (Affymetrix, Thermo Fisher Scientific,
Schlieren, Switzerland) according to the manufacturer’s protocol. Re-
sults were analyzed with the Chromosome Analysis Suite (ChAS)
software (version 3.1.1.27; Affymetrix, Thermo Fisher Scientific).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 7.03
(GraphPad Software, La Jolla, CA, USA).
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